There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced “autoprotection”, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced “autoimpairment”. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic.

There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced “autoprotection”, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced “autoimpairment”. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic.